Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study

OBJECTIVES: Many patients with Cushing's disease (CD) require chronic pharmacotherapy to control their hypercortisolism. We evaluated the efficacy and safety of long‐acting pasireotide during a long‐term extension study in patients with CD. DESIGN: Open‐label extension to a 12‐month Phase III s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Endocrinol (Oxf)
Auteurs principaux: Fleseriu, Maria, Petersenn, Stephan, Biller, Beverly M. K., Kadioglu, Pinar, De Block, Christophe, T'Sjoen, Guy, Vantyghem, Marie‐Christine, Tauchmanova, Libuse, Wojna, Judi, Roughton, Michael, Lacroix, André, Newell‐Price, John
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
ORIGINAL ARTICLES
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899900/
https://ncbi.nlm.nih.gov/pubmed/31465533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cen.14081
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires